TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dermata Therapeutics ( (DRMA) ) just unveiled an update.
On November 7, 2025, Dermata Therapeutics announced an increase in the maximum aggregate offering amount of its common stock by $1,792,315 under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This move follows a previous sale of $1,662,142 worth of shares, potentially impacting the company’s financial strategy and market positioning.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies for dermatological conditions.
Average Trading Volume: 136,448
Technical Sentiment Signal: Sell
Current Market Cap: $2.16M
See more data about DRMA stock on TipRanks’ Stock Analysis page.